Formulation of Neulasta® (pegfilgrastim)
- 1 January 2008
- journal article
- review article
- Published by Elsevier in Advanced Drug Delivery Reviews
- Vol. 60 (1) , 50-58
- https://doi.org/10.1016/j.addr.2007.04.017
Abstract
No abstract availableKeywords
This publication has 41 references indexed in Scilit:
- Pharmacokinetic Consequences of PegylationDrug Delivery, 2006
- Common Structural Stability Properties of 4-Helical Bundle Cytokines: Possible Physiological and Pharmaceutical ConsequencesCurrent Pharmaceutical Design, 2004
- The Design and Development of Pegfilgrastim (PEG-rmetHuG-CSF, Neulasta®)Current Pharmaceutical Design, 2004
- Effect of pegylation on pharmaceuticalsNature Reviews Drug Discovery, 2003
- Chemistry for peptide and protein PEGylationAdvanced Drug Delivery Reviews, 2002
- PEG drugs: an overviewJournal of Controlled Release, 2001
- Biomedical and biotechnological applications of PEG- and PM-modified proteinsTrends in Biotechnology, 1995
- FilgrastimDrugs, 1994
- Cysteine 17 of recombinant human granulocyte-colony stimulating factor is partially solvent-exposedProtein Journal, 1993
- The structure of granulocyte-colony-stimulating factor and its relationship to other growth factors.Proceedings of the National Academy of Sciences, 1993